Dexamethasone Down-regulates Osteocalcin in Bone Cells through Leptin Pathway by Chen, Shu-Mei et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dexamethasone Down-regulates Osteocalcin in Bone Cells
through Leptin Pathway
Citation for published version:
Chen, S-M, Peng, Y-J, Wang, C-C, Su, S-L, Salter, D & Lee, H-S 2018, 'Dexamethasone Down-regulates
Osteocalcin in Bone Cells through Leptin Pathway' International Journal of Medical Sciences , vol 15, no. 5,
pp. 507-516. DOI: 10.7150/ijms.21881
Digital Object Identifier (DOI):
10.7150/ijms.21881
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
International Journal of Medical Sciences
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Jul. 2018
Int. J. Med. Sci. 2018, Vol. 15 
 
 
http://www.medsci.org 
507 
International Journal of Medical Sciences 
2018; 15(5): 507-516. doi: 10.7150/ijms.21881 
Research Paper 
Dexamethasone Down-regulates Osteocalcin in Bone 
Cells through Leptin Pathway 
Shu-Mei Chen1,2, Yi-Jen Peng3, Chih-Chien Wang4, Sui-Lung Su5, Donald M Salter6, Herng-Sheng Lee7 
1. Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC. 
2. Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan, ROC. 
3. Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC 
4. Department of Orthopedics, Taipei Medical University Hospital, Taipei, Taiwan, ROC. 
5. School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC. 
6. Centre for Genomic and Molecular Medicine, IGMM, University of Edinburgh, Edinburgh, UK  
7. Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.  
 Corresponding author: Dr. H.S. Lee, Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, No.386, Dazhong 1st Rd., 
Zuoying Dist., Kaohsiung City 81362, Taiwan (R.O.C.) Tel: 886-7-3422121ext.8161; Fax: 886-7-3422288; E-mail: hlee@vghks.gov.tw 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2017.07.12; Accepted: 2018.01.05; Published: 2018.03.08 
Abstract 
Glucocorticoid therapy, especially at higher doses, is associated with significant adverse side effects 
including osteoporosis. Leptin, secreted from adipose tissue, has diverse effects on bone tissue 
regulation. As glucocorticoids stimulate leptin synthesis and secretion directly in adipose tissue we 
hypothesised that dexamethasone (DEX) induced osteoporosis may, in part, be mediated by an 
osteoblast dependent leptin-leptin receptor pathway. Human bone cells expressed leptin and leptin 
receptors (Ob-Ra and Ob-Rb). DEX increased leptin, Ob-Ra and Ob-Rb expression in a 
dose-dependent manner while decreasing expression of osteocalcin. In the presence of leptin, Cbfa1 
and osteonectin expression showed no significant change, whereas osteocalcin expression was 
decreased. Recombinant human quadruple antagonist leptin suppressed DEX-induced osteocalcin 
downregulation. The signaling pathway involved up-regulation of JAK2. In conclusion, upregulation 
of leptin and Ob-Rb in human bone cells by DEX is associated with down-regulation of osteocalcin 
expression. The down regulation of osteocalcin by DEX was partially through a leptin 
autocrine/paracrine loop. Adverse effects of DEX on the skeleton may be modified by targeting 
leptin signaling pathways. 
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Introduction 
Glucocorticoids are important endocrine 
regulators of a wide range of cardiovascular, 
immunologic and metabolic functions postnatally and 
have multiple roles in development. Glucocorticoids 
bind to the cytoplasmic glucocorticoid receptor (GR) 
that dimerizes and translocates to the nucleus and 
binds to specific glucocorticoid response elements 
(GRE) [1]. Synthetic glucocorticoids such as 
prednisone, prednisolone, methylprednisone acetate 
and dexamethasone are used widely for treatment of 
inflammatory diseases including asthma, 
inflammatory bowel disease, and rheumatoid arthritis 
[2]. Treatment, especially at higher doses, is however 
associated with significant adverse side effects 
including osteoporosis [3, 4]. 
Glucocorticoid induced osteoporosis, in common 
with other forms of osteoporosis such as that resulting 
from gonadal insufficiency and high intake of alcohol, 
is characterized by loss of bone mass and 
deterioration of the microarchitectural bone structure 
leading to an increased susceptibility to fractures [5]. 
Glucocorticoids have direct effects on osteoblast, 
osteocyte, and osteoclast function resulting in reduced 
bone remodeling and diminished repair of 
microdamage to bone. In addition to the direct effects 
on bone cells, glucocorticoids also have effects on the 
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intestine, kidneys, gonads, and probably parathyroid 
glands, which may contribute to osteoporosis [6].  
Leptin secreted from white adipocytes is 
implicated in the regulation of food intake and energy 
expenditure in rodents and humans [7]. It binds to the 
leptin receptor (Ob-R) which is expressed as several 
different isoforms [8]. Leptins and leptin receptors 
have now been shown to be expressed in a number of 
organs and tissues in addition to adipose tissue [9, 10]. 
Leptins have diverse effects on bone tissue regulation 
with leptin receptor mutations [11]. The predominant 
effect of leptins on bone metabolism appears to be 
through the hypothalamus by activation of the 
sympathetic nervous system [12]. Nevertheless, 
evidence of a likely direct effect in bone appears likely 
as leptin induce bone growth and formation [13]. As 
glucocorticoids stimulate leptin synthesis and 
secretion directly in adipose tissue [14, 15] we 
hypothesised that glucocorticoid induced 
osteoporosis may, in part, be mediated by an 
osteoblast dependent leptin-leptin receptor pathway.  
Materials and Methods 
Materials 
 Dexamethasone (DEX) was purchased from 
Sigma-Aldrich Inc. (Steinheim, Germany). 
Recombinant human leptin/OB was purchased from 
R&D Systems Inc. (Minneapolis, MN, USA). The 
leptin antagonist, recombinant human leptin 
quadruple mutant (LQM), was obtained from 
RayBiotech, Inc. (Norcross, GA, USA). 
Human bone cell (HBC) isolation and culture 
 Bone samples were from surgical discard tissue 
obtained, with consent, at knee joint arthroplasty from 
Taiwanese patients with osteoarthritis (OA) (n = 12, 
mean age 69.5 years, range 58–83 years). All 
procedures were reviewed and approved by an 
institutional human research committee (TMU-JIRB 
No.201305003). Cortical and subchondral bone 
fragments were minced, incubated in antimicrobial 
solution for 4 h at room temperature, and washed 
with phosphate-buffered saline (PBS, pH 7.4) by 
vortex vigorously to remove fatty components. Bone 
fragments were maintained in modified McCoy’s 5A 
medium (Gibco, Carlsbad, CA, USA) supplemented 
with 10% fetal bovine serum (FBS) (Gibco), 100 
IU/mL penicillin (Gibco) and 100 µg/mL 
streptomycin (Gibco). Initial bone cultures were 
established in petri dishes (Orange Scientific, 
Braine-I’Alleud, Belgium) before passage into tissue 
culture flasks (Orange Scientific). Cell populations 
grown from these bone tissues demonstrated 
osteoblast-like characteristics with production of 
alkaline phosphatase. These cells showed no 
immunoreactivity with an anti-S100 antibody 
(DakoCytomation, Glostrup, Denmark) excluding 
growth of adipocytes (data not shown). Cells between 
passages 3 to 5 were used [16].  
 HBCs were seeded at 1 × 105 cells/dish and 
grown as a monolayer for 5 days in 55 mm tissue 
culture Petri dishes. Cells were washed with sterile 
PBS twice, placed in serum-free media for 2 hrs, and 
then co-incubated with 0, 1, 10, and/or 100 nM of 
dexamethasone at 37°C for 24 hrs. Leptin (20 ng/mL) 
and the leptin antagonist LQM (500 ng/mL) were also 
used in the functional studies as stated in appropriate 
experiments. Controls were cultures in serum-free 
media incubated for the same time periods. 
Immunofluorescence  
 Cells were cultured at a concentration of 1 × 105 
as a monolayer for 5 days in 55 mm tissue culture 
Petri dishes. The cells were washed with 5 ml TBS and 
then fixed using 2 ml of a 1:1 methanol/acetone 
mixture per dish for 20 min at －20°C before further 
washing with PBS. The cells were then incubated 
sequentially with primary antibody overnight at 4oC. 
The antibodies used were polyclonal anti-leptin (1:10 
dilution) (Upstate, Temecula, CA, USA) and 
monoclonal anti-Ob-R (1:100) (Santa Cruz 
Biotechnology, Inc., CA, USA) antibodies. Following 
washing in PBS cells were incubated for 2 h in 
darkness with goat-anti-rabbit or goat-anti-mouse IgG 
conjugated with fluorescein (1:50) (Jackson 
Immunoresearch Laboratories, Inc., PA, USA), 
washed again and mounted in buffered glycerin 
before viewing by fluorescence microscopy 
(Olympus). Negative controls without primary 
antibodies were performed for each test. 
Reverse transcription-polymerase chain 
reaction (RT-PCR) 
 Total RNA was isolated from cultures of HBC 
using easy-BLUETM Total RNA Extraction Kit 
(iNtRON Biotechnology, Gyeonggi-do, Korea). 
RT-PCR protocol has been described previously from 
our laboratory [17]. Specific primers and amplifying 
conditions were shown in Table 1. All PCR products 
were size fractionated by 1.5% agarose gel 
electrophoresis, and DNA bands were visualized by 
staining the gel with 0.1 µg/ml ethidium bromide.  
Western blotting and ELISA 
 Following stimulation, cells were immediately 
washed with sterile PBS and protein extracted using 
the CNMCS compartmental protein extraction kit 
according to the manufacturer’s instructions 
(Biochain Institute, Inc., Hayward, CA, USA). In some 
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experiments cells were lysed in situ with ice-cold lysis 
buffer containing 1% Igepal (Sigma), 100 µM Na3VO4, 
and protease inhibitor cocktail tablet (Roche 
Diagnostics, Mannheim, Germany) at 4°C for 15 min 
to obtain whole cell protein. Protein concentration 
was determined by the Lowry method. Equal 
amounts of protein (10 µg) were loaded onto 7.5% 
SDS-polyacrylamide gel and following 
electrophoresis were transferred to polyvinylidene 
fluoride (PVDF) membranes (Millipore Immobilon-P, 
Sigma). Membranes were blocked overnight at 4°C 
with 2% BSA in TBST (12.5 mM Tris/HCl, pH 7.6, 137 
mM NaCl, 0.1% Tween 20). After washing with TBST, 
blots were incubated at 4°C with antibodies against 
Ob-R (B-3) (1:500 dilution), osteocalcin, JAK2 or 
phospho-JAK2 (1:1000) (Cell Signaling Technology, 
Inc., Danvers, MA, USA) diluted in TBST, washed 
again before incubation with HRP-labeled secondary 
antibody (1:1000) for 1 h at room temperature. 
Membranes were rewashed extensively and binding 
detected using the Enhanced Chemiluminescence 
Western blotting detection system, according to the 
manufacturer’s instructions. Tubulin expression as 
loading control was assessed with the mouse 
monoclonal antibody Tubulin-alpha Ab-2 (1:10000) 
(NeoMarkers, Fremont, CA, USA). 
 For measurement of leptin levels culture 
supernatants were collected and leptin concentrations 
were measured by ELISA (R&D) according to the 
manufacturer’s instructions. 
Animal model analysis 
 The db/db (B6.BKS(D)−Leprdb/J; deficient in 
leptin receptors) and wild-type (C57BL/6J) male mice 
at 7 months of age were used [18]. Experiments were 
approved by the local Institutional Review Board 
(IACUC-15-102) and were performed in adherence to 
the National Institutes of Health Guidelines for the 
treatment of experimental animals. Fresh bone tissues 
from mice were collected for primary bone cell 
cultures which follow the previous HBC protocol. 
Osteocalcin gene expression levels in bone cells from 
the db/db and wild type mice (n=3 each) treated with 
either DEX or solvent for 24 h were determined by 
real-time PCR. Complementary DNA was produced 
from osteoblastic mRNA (5 µg) using the SuperScript 
II RNase H- Reverse Transcriptase kit (Invitrogene, 
Carlsbad, CA). Triplicates from each plate were used. 
The gene expression was analyzed by Applied 
Biosystems Step-One system. Primer sequences are as 
follows: m-osteocalcin, forward 5'-GACCTCACAGA 
TGCCAAG-3' and reverse 5'-TCACAAGCAGGGTT 
AAGC-3'; m-GAPDH, forward 5'- TCACCACCATGG 
AGAAGGC-3' and reverse 5'- GCTAAGCAGTTGGT 
GGTGCA-3'.  
Statistical analysis 
 Bands were analyzed using gel documentation 
system (Bio-Profil, Bio-1D version 99, Viogene, USA). 
The values were expressed as ratio of the band 
intensity of the target gene to the internal control 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) gene or the target protein to the internal 
control tubulin. Variance and P values were analyzed 
by Alphaimager 1220 V5.5 (Alpha Innotech 
Corporation, San Leandro, CA, USA). A Student’s t 
test was used for statistical comparison between 
groups. A P value of less than 0.05 was considered 
statistically significant. 
Results 
Expression of leptin and Ob-R in 
human bone cells  
 Leptin and Ob-R were shown to be 
expressed by HBC in monolayer culture at 
the protein and gene level by 
immunofluorescence and RT-PCR 
respectively (Fig. 1). RT-PCR 
demonstrated expression of both Ob-Rb 
(long) and Ob-Ra (short) forms of Ob-R. 
Effects of leptin on HBC gene 
expression 
 To examine potential effects of leptin 
on bone homeostasis primary HBC 
cultures were incubated with leptin 
peptide and gene expression of Cbfa1 and 
bone matrix molecules assessed. 
Following incubation with 20 ng/ml 
leptin for 24 hours there was a significant 
 
Table 1. Specific primers and amplification conditions. 
Gene Primers No. of 
cycles 
Annealing 
temp (℃) 
Product 
size (base 
pairs) 
Leptin F: 5'-GCATTGGGGAACCCTGTG-3' 
R: 5'-AGCACCCAGGGCTGAGGT-3' 
35 58 499 
Ob-Ra F: 5'-TTGTGCCAGTAATTATTTCCTCTT-3' 
R: 5'-AGTTGGCACATTGGGTTCAT-3' 
30 50 200 
Ob-Rb F: 5'-GCTATTTTGGGAAGATGT-3' 
R: 5'-TGCCTGGGCCTCTATCTC-3' 
40 58 501 
Osteocalcin F: 5'-ATGAGAGCCCTCACACTCCTC-3' 
R: 5'-CGTAGAAGCGCCGATAGGC-3' 
30 60 291 
Osteonectin F: 5'-ACATGGGTGGACACGG-3' 
R: 5'-CCAACAGCCTAATGTGAA-3' 
35 52 405 
C-I  F: 5'-GATGGATTCCAGTTCGAGTATG-3' 
R: 5'-GTTTGGGTTGCTTGTCTGTTTC-3' 
30 60 480 
AP F: 5'-ACGTGGCTAAGAATGTCATC-3' 
R: 5'-CTGGTAGGCGATGTCCTTA-3' 
30 56 476 
Cbfa1  F: 5'-CCCCACGACAACCGCACCAT-3' 
R: 5'-CACTCCGGCCCACAAATC-3' 
30 64 289 
GAPDH F: 5'-GGTGAAGGTCGGAGTCAACG-3' 
R: 5'-CAAAGTTGTCATGGATGACC-3' 
25 56 497 
 C-I: Collagen type I 
 AP: Alkaline phosphatase 
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decrease, approximately 25%, in osteocalcin gene 
expression by HBC (Fig. 2). There was no change in 
Cbfa1, osteonectin, collagen type I, and alkaline 
phosphatase gene expression under identical 
conditions. 
 
Fig. 1 Expression of leptin and Ob-R in cultures of human bone cells. By immunofluorescence HBC showed expression of lepin (A, negative control; B, anti-leptin 
antibody) and Ob-R (C, negative control; D, anti-Ob-R antibody). (All figures, 400x). Expression of leptin, Ob-Ra (short form), and Ob-Rb (long form) demonstrated 
by RT-PCR in three representative samples of HBC derived from different patients (E). 
 
Fig. 2 Effects of leptin on HBC gene expression of cbfa1, osteocalcin, osteonectin, collagen type I, and alkaline phosphatase. Incubation of HBC with leptin significantly 
decreased the osteocalcin expression (n=5, ***p=0.0003). There was no significant change in expression of the other molecules examined.  
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Effects of dexamethasone on HBC 
 All HBC cultures expressed alkaline 
phosphatase and its expression was not influenced by 
incubation with DEX under the experimental 
conditions (results not shown). There was a 
dose-dependent effect of DEX on leptin and Ob-R 
expression. As shown by semi-quantitative analysis 
leptin gene expression increased approximately 
3.1-fold and 4.9-fold following treatment with 10 and 
100 nM of DEX respectively (Fig. 3A). This was 
associated with increased levels of leptin in the 
culture media as measured by ELISA (Fig. 3B). Basal 
levels of leptin were 4.7 ± 2.0 pg/mL rising to 14.1 ± 
7.9 pg/mL (3.2-fold increase) and 11.9 ± 3.8 pg/mL 
(2.7-fold) following treatment with 10 and 100 nM of 
DEX respectively. Ob-R gene expression increased 
approximately 1.8-fold and 2.2-fold following 
treatment with 10 and 100 nM of DEX respectively 
(Fig. 3C). Western blotting demonstrated a 3.3-fold 
and 5.4-fold increase in Ob-R protein expression by 
HBC following incubation with 10 and 100 nM DEX 
(Fig. 3D).  
 
 
Fig. 3 Effects of dexamethasone (DEX) on HBC. A. Increased leptin RNA levels induced by DEX treatment were identified at the concentrations of 10 and 100 nM 
(*p=0.015, **p=0.00035, respectively). B. By ELISA, release of leptin into culture supernatant increased significantly at DEX 10 and 100 nM (*p=0.016, **p=0.0018, 
respectively). C. Increased Ob-R RNA levels induced by DEX treatment were identified at the concentrations of 10 nM (Ob-Ra ***p=0.0009, Ob-Rb *p=0.002) and 
100 nM (Ob-Ra ***p=0.0009, Ob-Rb **p=0.019). D. Significant increase of Ob-R protein at DEX 10 and 100 nM was also seen (*p=0.032, **p=0.009, respectively). 
(All n=6) 
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Roles of leptin in DEX regulation of HBC 
differentiation and bone matrix gene 
expression.  
 As DEX increased leptin and Ob-R expression in 
bone cells we investigated whether the effects of DEX 
on HBC differentiation and regulation of bone matrix 
gene expression was through a leptin dependent 
mechanism. Collagen type I and alkaline phosphatase 
gene expression did not alter significantly following 
treatment with DEX over a concentration range of 
1-100 nM (results not shown). There was minimal 
(9%) but statistically significant effect of DEX on 
expression of osteonectin gene expression at the 
highest concentration whilst Cbfa1 expression was 
increased by approximately 1.5-fold and 1.8-fold 
following treatment with 10 and 100 nM of DEX 
(results not shown). DEX had a dose dependent effect 
on osteocalcin gene expression with a significant 
decrease seen at both 10 and 100 nM (39% decrease) 
concentrations (Fig. 4A). The addition of leptin 
antagonist (A500, 500 ng/mL) blocked the inhibitory 
effects of DEX on osteocalcin gene expression (Fig. 
4B). The osteocalcin protein expression by DEX 
showed a similar pattern to the gene expression (Fig. 
4C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Effect of DEX on gene 
expression +/- leptin antagonist. 
A. Osteocalcin gene expression 
was significantly down-regulated 
by 10 and 100 nM DEX (*p=0.03, 
**p=0.004, respectively). B. The 
presence of the leptin antagonist 
(A500, 500 ng/mL) showed partial 
recovery of osteocalcin down 
regulation induced by DEX (100 
nM) (**p=0.003 vs. 0, #p=0.035 
vs. DEX 100). Upper panel, a 
representative gel; lower panel, 
semi-quantitative data. C. 
Osteocalcin protein expression 
was also significantly 
down-regulated by 10 and 100 nM 
DEX (*p<0.05). (n=6) 
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Osteocalcin gene expression by DEX in mouse 
bone cells 
 The effect of DEX in the osteocalcin gene 
expression of primary osteoblastic cells of wild-type 
and db/db mice was tested. Cells treated with 100 nM 
of DEX showed significant downregulation of 
osteocalcin in mice of wild type, but not in db/db 
mice (Fig. 5A). The post-receptor leptin signaling 
molecule to osteocalcin expression may be associated 
with the protein phosphorylation of JAK2 (Fig. 5B). 
 
 
Fig. 5 Animal study in vitro. A. Inhibition of osteocalcin gene expression by DEX in primary osteoblastic cells of wild-type and db/db mice. Cells were treated with 
100 nM of DEX for 24 h. Osteocalcin gene expression showed significant decrease in cells from wild-type mice, but not in db/db mice. B. In cells from wild-type mice, 
the post-receptor signalling molecule was associated with phophorylation of JAK2 in both DEX and leptin (Lep 20, leptin 20 ng/mL) treatment. In cells from db/db 
mice, the tendency of JAK2 phosphorylation was not significant. The data expressed as mean ± SD. * denotes P < 0.05 as compared to control cultures without DEX 
treatment (n=3). 
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Discussion 
 In the current study we have shown that leptin 
and Ob-R are expressed by HBC in monolayer culture 
and leptin decreases osteocalcin gene expression in 
these cells. DEX increases leptin and Ob-R expression 
in HBC and effects of DEX on osteocalcin expression 
which is also confirmed by animal model, appear to 
be, at least in part, through a novel leptin dependant 
pathway. 
 The leptin-leptin receptor pathway has been 
implicated in the control of a wide range of 
physiological processes including inflammation, 
angiogenesis, immune function, haematopoiesis, lipid 
metabolism, insulin action, and function of the 
reproductive system [19, 20]. In pathological settings 
the leptin-leptin receptor pathway may have roles in 
cancer cell proliferation, invasion and metastasis [21]. 
Effects of leptin on bone are complicated with both 
central and peripheral effects. Genetically 
leptin-deficient mice, have a decreased trabecular 
volume in long bones, but an increased vertebral bone 
mass. Leptin replacement either centrally or 
peripherally corrects these abnormalities but doses of 
leptin required centrally are much lower than those 
needed peripherally indicating the existence of a 
pathway confined to the brain [22]. Centrally, leptin 
acting through a central hypothalamic relay inhibits 
bone mass via the sympathetic nervous system [23]. 
The leptin dependent regulation of bone mass occurs 
through via the β2-adrenergic receptor as 
β2-adrenergic receptor-null mice have a similar bone 
phenotype, without metabolic abnormalities. The 
sympathetic signaling directly affects osteoblasts 
which express β2-adrenergic receptors, controlling 
proliferation and differentiation through the 
regulation of AP-1 and genes involved in the 
molecular clock [24]. Sympathetic stimulation of 
osteoblasts increases expression of the receptor 
activator of nuclear factor B ligand (RANKL). The 
current study confirms reports of leptin and leptin 
receptor expression in human bone cells indicating 
roles for peripheral activity in regulation of bone 
turnover through paracrine and autocrine routes [25] 
and demonstrates that expression of osteocalcin by 
bone cells may be regulated by the leptin-leptin 
receptor pathway. 
 In the present study, experiments were 
undertaken using bone cells derived from OA 
patients rather than normal adult bone and it is 
unclear whether the findings are unique to OA 
patients or are more widely applicable. Leptin levels 
are reported to be elevated in patients, particularly 
females, with knee OA [26, 27] and synovial fluid 
leptin concentrations are closely related to the 
radiographic severity of OA [28]. Although it is 
accepted that OA is associated with a high bone 
mineral density (BMD) and that OA is generally 
inversely related to osteoporosis, the relationship 
between OA and osteoporosis remains controversial. 
Indeed, the relationship between OA and 
osteoporosis may differ by disease site, stage or 
pathogenetic basis [29, 30]. Furthermore, the 
pathogenesis of OA in non-obese patients is likely to 
be different to those of obese individuals where there 
is a significant contribution to the disease process 
through the action of pro-inflammatory adipokines 
such as leptin. Recently, the idea that obesity is 
protective against fracture is being increasingly 
questioned with the suggestion now that obesity is a 
risk factor for certain fractures [31].  
 Previous studies have shown that treatment of 
rats with DEX results in decreased bone mineral 
density and mineralized matrix [32-35]. One of the 
mechanisms of DEX-induced bone loss is thought to 
be a direct effect on the osteoblast differentiation [36] 
via MAPK signalling although glucocorticoid-treated 
mice also demonstrate the change of apoptosis and 
autophagy in osteoblasts and osteocytes [37]. DEX 
could downregulate the osteogenic markers including 
Runt-related transcription factor 2 (Runx2), alkaline 
phosphatase and osteocalcin [38]. DEX induces 
histone deacetylase 6 (HDAC6) expression which 
binds to glucocorticoid receptor and may inhibit the 
expression of osteocalcin [39]. However, the 
mechanism(s) by which DEX influences bone cell 
differentiation is not fully understood. 
Glucocorticoids, such as dexamethasone have a 
marked inhibitory effect on bone formation in vivo. In 
vitro studies on isolated osteoblasts show both 
catabolic and anabolic effects although the relevance 
of the latter is unclear. Pharmacological 
concentrations of glucocorticoids in vitro inhibit 
osteoblast proliferation and function whilst increasing 
osteoblast and osteocyte apoptosis. Similarly 
dexamethasone decreases proliferation of osteoclast 
precursors, reduces bone resorption and induces 
apoptosis in mature osteoclasts, with blunting of 
osteoclast activity and function having an additional 
indirect effect of further suppressing osteoblast 
function [39]. In the present study DEX alters 
expression of osteoblast differentiation markers 
inducing a decrease in osteocalcin gene expression 
and upregulation of Cbfa1 at concentrations where 
increases in leptin and Ob-R expression are also seen. 
Blockade of the effects of DEX on osteocalcin 
expression by a leptin antagonist suggests that leptin 
signalling may contribute to the effects of DEX on 
bone cells. The post-receptor leptin signaling 
molecule to osteocalcin expression may be associated 
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with the protein phosphorylation of JAK2 which is 
consistent with other investigations [40].  
 Leptin has both anabolic and catabolic activity in 
bone. Leptin promotes bone differentiation in bone 
mesenchymal stem cells directly [41] whilst increasing 
RANKL expression by activating β-2 adrenergic 
receptors on osteoblasts through the sympathetic 
nervous system and increasing the activity of 
osteoclasts in bone resorption [42]. There is increasing 
interest in the relationship between bone and energy 
metabolism with leptin and osteocalcin having key 
roles [43-45]. Whilst many of the potential interactions 
and effects are a result of endocrine signalling local 
mechanisms of regulation of osteocalcin and leptin 
levels in bone may have fine tuning effects. 
Production of leptin by cells of the osteoblast lineage 
and autocrine / paracrine activity are likely to play a 
significant role in both normal and pathological bone 
turnover including responses to mechanical loading 
[45,46]. Pharmacological regulation of leptin activity 
may provide an additional means by which primary 
or secondary abnormalities of bone turnover in a 
clinical setting can be positively influenced. 
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